Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Good afternoon, and welcome to the 2022 Jefferies Global Healthcare Conference. It's my great pleasure to introduce DA Gros, CEO of Eledon Pharmaceuticals.
Thanks, Shan, and thank you to Jefferies for having us today. I'll be making forward-looking statements, so I encourage you to please review this slide as well as our disclaimer.
We founded Eledon almost two years ago in its current state now with a goal to create a company that would be focused around CD40 and CD40 ligand therapeutics.
Our goal and strategy when we formed the company was to create a biotech that would be able to prosecute our lead asset, tegoprubart, previously known as AT-1501, in up to four different indications. So that's what we've been working on since. Today, I'll give you an update of where we are. And we are in a good position from a cash perspective where we'll be able to generate -- we expect to generate data across all four of these indications, and we have sufficient capital today to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |